103 related articles for article (PubMed ID: 6447114)
1. Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer.
Cannon GB; Dean JH; Herberman RB; Perlin E; Reid J; Miller C; Lang NP
Int J Cancer; 1980 Jan; 25(1):9-17. PubMed ID: 6447114
[TBL] [Abstract][Full Text] [Related]
2. The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative responses of cancer patients to mitogens and alloantigens.
Dean JH; Connor R; Herberman RB; Silva J; McCoy JL; Oldham RK
Int J Cancer; 1977 Sep; 20(3):359-70. PubMed ID: 143457
[TBL] [Abstract][Full Text] [Related]
3. Failure of cell-mediated effector mechanisms in lung cancer.
Feo Figarella E; Morillo F; Blanca I; Bianco NE
J Natl Cancer Inst; 1984 Jul; 73(1):1-6. PubMed ID: 6330420
[TBL] [Abstract][Full Text] [Related]
4. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
Xu XY; Lin N; Li YM; Zhi C; Shen H
Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236
[TBL] [Abstract][Full Text] [Related]
5. Loss of isoantigens A, B, and H in carcinoma of the lung.
Davidsohn I; Ni LY
Am J Pathol; 1969 Nov; 57(2):307-34. PubMed ID: 4902573
[No Abstract] [Full Text] [Related]
6. Demonstration of specific cell-mediated anti-tumor immunity in lung cancer to autologous tissue extracts.
Dean JH; Jerrells TR; Cannon GB; Kibrite A; Baumgardner B; Weese JL; Silva J; Herberman RB
Int J Cancer; 1978 Oct; 22(4):367-77. PubMed ID: 212376
[TBL] [Abstract][Full Text] [Related]
7. Immunocytology of cancer.
Davidsohn I; Ni LY
Acta Cytol; 1970 May; 14(5):276-82. PubMed ID: 4935158
[No Abstract] [Full Text] [Related]
8. Immunological monitoring and immunotherapy in carcinoma of the lung.
Weese JL; Herberman RB; Perlin E; Mills M; Heims W; Blom J; Green D; Reid J; Bellinger S; Law I; McCoy JL; Dean JH; Cannon GB; Djeu J
Int J Cancer; 1976 Dec; 18(6):739-49. PubMed ID: 186417
[TBL] [Abstract][Full Text] [Related]
9. Immunologic impairment in bronchogenic carcinoma: a study of lymphocyte response to phytohemagglutinin.
Han T; Takita H
Cancer; 1972 Sep; 30(3):616-20. PubMed ID: 4342406
[No Abstract] [Full Text] [Related]
10. Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course. II. Evaluation of 69 patients with lung carcinoma.
Vánky F; Péterffy A; Böök K; Willems J; Klein E; Klein G
Cancer Immunol Immunother; 1983; 16(1):17-22. PubMed ID: 6605800
[TBL] [Abstract][Full Text] [Related]
11. [Cytotoxicity of lymphocytes against autologous cultured primary lung cancer cells in relation to histological type and clinical stage].
Kimura H; Yamaguchi Y; Kadoyama C; Matsumoto A
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2175-81. PubMed ID: 3013100
[TBL] [Abstract][Full Text] [Related]
12. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
13. Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer.
Fariñas MC; Rodriguez-Valverde V; Zarrabeitia MT; Parra-Blanco JA; Sanz-Ortiz J
Cancer; 1991 Sep; 68(6):1279-84. PubMed ID: 1873782
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood lymphocytes and their subpopulations in lung carcinoma.
Zółtowska A; Skokowski J; Mlekodaj S; Boj E
Arch Immunol Ther Exp (Warsz); 1980; 28(4):649-53. PubMed ID: 6970027
[TBL] [Abstract][Full Text] [Related]
15. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
[TBL] [Abstract][Full Text] [Related]
16. [A study about the ability of interleukin-2 production, interleukin-2 receptor expression by lymphocytes from patients with lung cancer].
Liu SB
Zhonghua Jie He He Hu Xi Za Zhi; 1992 Dec; 15(6):349-51, 380. PubMed ID: 1339618
[TBL] [Abstract][Full Text] [Related]
17. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
18. Detection of circulating lung tumor antigen-sensitive T lymphocytes in the early stages of lung cancer.
Ramey WG; Hashim GA; Munther AS; Swistel AJ; Burrows WB; Fitzpatrick HF
Surgery; 1980 Aug; 88(2):202-7. PubMed ID: 6967233
[No Abstract] [Full Text] [Related]
19. Immune reactivity in primary carcinoma of the lung and its relation to prognosis.
Wanebo HJ; Rao B; Miyazawa N; Martini N; Middleman MP; Oettgen HF; Beattie EJ
J Thorac Cardiovasc Surg; 1976 Sep; 72(3):339-50. PubMed ID: 183063
[TBL] [Abstract][Full Text] [Related]
20. Suppression of T-cell response in autologous mixed lymphocyte-tumor culture by large granular lymphocytes.
Uchida A; Klein E
J Natl Cancer Inst; 1986 Mar; 76(3):389-98. PubMed ID: 2419621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
